- Conditions
- Healthy Volunteers, Diabetes Mellitus, Type 1
- Interventions
- 18 F-FP-DTBZ, PET Scanning
- Drug · Radiation
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 1,666
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Diabetes Assistant (DiAs)
- Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Santa Barbara, California • Charlottesville, Virginia
- Conditions
- Type 1 Diabetes
- Interventions
- CT-868, Placebo, Victoza
- Drug
- Lead sponsor
- Carmot Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 1 Diabetes
- Interventions
- Dexcom G7 rtCGM, Capillary Blood glucose Testing (POC)
- Device · Diagnostic Test
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- DREAM intervention
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Davis, California • Los Angeles, California • San Francisco, California
- Conditions
- Type 1 Diabetes
- Interventions
- FAMS-T1D, Digital resources for diabetes
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Salt Lake City, Utah
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Placebo, Study Medication (MBX-2982), No medication for this group
- Drug · Other
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Coronary Artery Disease, Type 1 Diabetes Mellitus
- Interventions
- Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
- Interventions
- DM Discharge Toolkit
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Type 1 Diabetes Mellitus, Glycemic Control
- Interventions
- Bayer DCA2000+ Hemoglobin A1c analyzer
- Device
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Microneedle, Subcutaneous insulin catheter
- Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Advanced Solid Malignancies
- Interventions
- MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 867 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 10
- States / cities
- Santa Rosa, California • Washington D.C., District of Columbia • Tinley Park, Illinois + 7 more
- Conditions
- Type 1 Diabetes
- Interventions
- Reinforcement for meeting targeted physical activity goals, Standard of Care
- Behavioral · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 13 Years to 24 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1
- Interventions
- R-5280, Placebo
- Drug · Other
- Lead sponsor
- Rise Therapeutics LLC
- Industry
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Plantation, Florida • Rochester, Minnesota • Dallas, Texas
- Conditions
- Type 1 Diabetes, Hypoglycemia, High Blood Sugar
- Interventions
- Dexcom G6 Continuous Glucose Monitor
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 1 Diabetes
- Interventions
- Glucagon Nasal Powder [Baqsimi]
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 4 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Boise, Idaho • Indianapolis, Indiana + 5 more
- Conditions
- Melanoma
- Interventions
- MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine
- Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin Degludec, Insulin Glargine
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 1 Diabetes
- Interventions
- Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
- Device
- Lead sponsor
- Marc Breton
- Other
- Eligibility
- 24 Months to 71 Months
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Stanford, California • Aurora, Colorado • Charlottesville, Virginia
- Conditions
- Type 1 Diabetes
- Interventions
- Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
- Drug
- Lead sponsor
- Sansum Diabetes Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia
- Conditions
- Type1diabetes
- Interventions
- AHCL pump, Video conferencing Application
- Device · Other
- Lead sponsor
- Children's Hospital New Orleans, LA
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
- Interventions
- Driving Decision Aid, Older Drivers Website
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 529 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Insulin Dependent Diabetes, ALT
- Interventions
- Betaine (trimethyglycine)
- Dietary Supplement
- Lead sponsor
- Southern California Institute for Research and Education
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 1
- States / cities
- Long Beach, California